Lipid-Altering Efficacy and Safety of Ezetimibe/Simvastatin Coadministered With Extended-Release Niacin in Patients With Type IIa or Type IIb Hyperlipidemia  by Guyton, John R. et al.
I
l
c
F
N
W
v
S
F
N
h
C
2
Journal of the American College of Cardiology Vol. 51, No. 16, 2008
© 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00
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Safety of Ezetimibe/Simvastatin
Coadministered With Extended-Release Niacin
in Patients With Type IIa or Type IIb Hyperlipidemia
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Joanne E. Tomassini, PHD,§ Andrew M. Tershakovec, MD, MPH§
Durham, North Carolina; Seattle, Washington; Nashville, Tennessee; and North Wales, Pennsylvania
Objectives This study evaluated the safety and lipid-altering efficacy of ezetimibe/simvastatin (E/S) coadministered with
extended-release niacin (N) in patients with type IIa or IIb hyperlipidemia.
Background Current guidelines recommend consideration of combination drug therapy to achieve optimal low-density
lipoprotein cholesterol (LDL-C) lowering and broader lipid-altering effects when treating hypercholesterolemic
patients at high risk for atherosclerotic cardiovascular events.
Methods In this 24-week multicenter, randomized, double-blind study, 1,220 type IIa or IIb hyperlipidemic patients were
randomized to treatment with E/S (10/20 mg/day)  N (titrated to 2 g/day), or N (titrated to 2 g/day), or E/S
(10/20 mg/day). Changes from baseline in LDL-C (primary) and other secondary variables were assessed in the
completers and modified intent-to-treat populations.
Results Coadministered E/S with N resulted in significantly greater reductions in LDL-C, non–high-density lipoprotein cho-
lesterol, triglycerides, apolipoprotein B, and lipid/lipoprotein ratios, compared with either agent alone (p 
0.001). The combination increased levels of apolipoprotein A-I and high-density lipoprotein cholesterol signifi-
cantly more than E/S (p  0.001), and reduced high-sensitivity C-reactive protein levels significantly more than
N (p  0.005). A significantly greater percentage of patients discontinued the study in the N (25.0%) and E/S 
N (23.3%) groups, compared with E/S (9.6%, p  0.001) because of clinical adverse experiences (primarily
flushing). Incidences of other clinical and laboratory adverse experiences (liver-, muscle-, and gastrointestinal-
related) were similar for all groups.
Conclusions Combination treatment with E/S plus N showed superior lipid-altering efficacy compared with N or E/S in type
IIa or IIb hyperlipidemia patients and was generally well tolerated aside from N-associated flushing. This combi-
nation offers an effective, broad, lipid-altering therapy with improvements in lipid effects beyond LDL-C in these
patients. (To Evaluate Ezetimibe/Simvastatin and Niacin [Extended Release Tablet] in Patients With High Choles-
terol; NCT00271817) (J Am Coll Cardiol 2008;51:1564–72) © 2008 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.03.003l
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008, accepted March 4, 2008.evels of high-density lipoprotein cholesterol (HDL-C) and
levated triglyceride levels. Current guidelines for the pre-
ention and treatment of CHD specify LDL-C lowering as
he primary goal of lipid-related therapy (1–3). Therapeutic
ifestyle change to reduce LDL-C and CHD risk is recom-
ended, including dietary measures such as decreasing
aturated fat and increased viscous fiber (3). However,
onsideration of combination therapies with broad lipid-
ltering effects is also recommended for treatment of high-
isk patients in need of further LDL-C lowering and/or
ith low HDL-C and high triglyceride levels (1–3).
Recent evidence suggests that increases in HDL-C levels
ay be associated with reductions in the incidence of CHD,
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April 22, 2008:1564–72 Ezetimibe/Simvastatin and Extended-Release Niacinegardless of LDL-C levels (4,5). Addition of HDL-C
aising to LDL-C lowering therapy may be beneficial in the
reatment of patients with combined dyslipidemia, who
haracteristically have low HDL-C levels, elevated tri-
lycerides, and a preponderance of small, dense LDL
articles (3,4). Given the increasing prevalence of diabetes,
etabolic syndrome, and obesity among patients with
ombined dyslipidemia, this therapeutic approach is of
articular importance (4,5).
Presently, niacin is the most effective agent available for
aising HDL-C levels. Niacin also decreases levels of triglyc-
rides, LDL-C, and lipoprotein(a), and increases lipoprotein
article size, thus representing a unique therapeutic option for
reatment of patients with combined dyslipidemia (4–7).
iacin has been used in clinical trials as monotherapy and
ombined with bile acid sequestrants, statins, clofibrate, and in
riple combination with cholestyramine and gemfibrozil. These
rials suggest that niacin, alone or as a component of broader
reatment, can reduce cardiovascular disease–related morbidity
nd mortality and also can slow the progression and/or induce
he regression of coronary atherosclerosis (6,15–21).
The dual cholesterol absorption and synthesis inhibitor
zetimibe/simvastatin (E/S) has been shown to be effective at
owering levels of LDL-C, non–HDL-C, and triglycerides in
atients with hypercholesterolemia (22–25). The coadminis-
ration of E/S with extended-release niacin (N) (Niaspan, Kos
harmaceuticals/Abbott, Abbott Park, Illinois) (7) might pro-
ide significant complementary LDL-C, non–HDL-C, and
riglyceride lowering and HDL-C raising effects, potentially
iving greater benefits than either agent alone.
This 24-week study is the initial phase of a longer study
n which we assessed the safety and efficacy of E/S  N in
ype IIa or IIb hyperlipidemic patients. The present study
ompared the lipid-altering effects of E/S N combination
herapy versus N and E/S. A Completers approach was used
or the primary efficacy analysis to describe the clinical effect
ssociated with the maximum N (2 g) prescribed dose,
nticipating that substantial numbers of patients would not
e able to tolerate higher doses of N (6,7,26). A supportive
econdary analysis was performed in the modified intent-
o-treat (mITT) population, in which the last blood sample
btained before drug discontinuation is considered to reflect
patient’s response to the drug.
ethods
tudy population and design. This 24-week study was
art 1 of a 64-week, multicenter, randomized, double-blind
tudy in patients with type IIa or IIb hyperlipidemia. The
rotocol was approved by appropriate institutional review
oards, and all patients provided informed written consent.
Men and women aged 18 years to 79 years with LDL-C
evels (130 to 190 mg/dl), triglyceride levels (500 mg/dl),
nd metabolic and clinical stability (e.g., euthyroid, creati-
ine 2 mg/dl, creatinine kinase 2 upper limit of
ormal [ULN], transaminases 1.5  ULN) were eligible oor inclusion in the study. After a
-week washout period, eligible
atients were randomized (5:2:2)
ia central allocation to E/S
10/20 mg) N (titrated to 2 g),
r E/S (10/20 mg), or N (titrated
o 2 g). All study personnel re-
ained blinded to treatment allo-
ation. During the first 12 weeks
f the study, N was increased by
00 mg every 4 weeks up to 2
/day from a 500 mg/day starting
ose. Patients were counseled to
ake N at bedtime with a low-fat
nack, aspirin (325 mg), or ibu-
rofen (200 mg) 30 min before
aking N, and to avoid alcoholic
nd hot beverages near the time
f taking N.
Patient enrollment was moni-
ored to achieve 30% to 50%
andomization of type IIa pa-
ients and to ensure balance in
ender. Patients were stratified at
andomization according to
aseline LDL-C (130 to 159
g/dl; 160 to 190 mg/dl) and triglyceride (200 mg/dl;
01 to 500 mg/dl) levels. In Part 2, comprising an additional
0 weeks of treatment, the E/S and E/S  N groups were
ontinued, whereas patients in the N-containing groups
ere randomly reassigned to those groups. Only Part 1
esults are presented here; Part 2 results will be analyzed and
resented separately.
The primary efficacy analysis was performed in the
ompleters population, which included all patients with a
aseline value, and who received 24 weeks of active study
herapy and had an on-treatment sample at the maximum
itrated dose of N (2 g). This analysis, rather than a
ITT-last observation carried forward (LOCF) approach,
as chosen because some patients are not able to tolerate 2 g
, and it was of interest to estimate and compare the
fficacy associated with N (2 g). The mITT analysis, which
ncluded all randomized patients who had baseline and at
east 1 post-baseline value, and an LOCF approach to
mpute any missing data for the Week 24 assessment, was
erformed as a secondary and supportive analysis.
Safety was assessed by monitoring clinical adverse expe-
iences (AEs) in all treated patients and laboratory AEs in
ll treated patients who had1 post-baseline measurement.
afety variables included the incidence of serum alanine
minotransferase and aspartate aminotransferase 3 
LN, serum creatine kinase (CK) 10  ULN with and
ithout muscle symptoms, discontinuation because of
ushing, gallbladder-related adverse experiences, cholecys-
ectomy, change from baseline in fasting glucose, and new
Abbreviations
and Acronyms
AE  adverse experience
Apo  apolipoprotein
CHD  coronary heart
disease
CK  creatine kinase
E/S  ezetimibe/
simvastatin
HDL-C  high-density
lipoprotein cholesterol
hsCRP  high-sensitivity
C-reactive protein
LDL-C  low-density
lipoprotein cholesterol
LOCF  last observation
carried forward
mITT  modified
intent-to-treat
N  extended-release
niacin
TC  total cholesterol
ULN  upper limit of
normalnset of diabetes (patients who had an AE related to a
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Ezetimibe/Simvastatin and Extended-Release Niacin April 22, 2008:1564–72iagnosis of diabetes, initiated an antidiabetic medication
uring the study, or had 2 consecutive fasting glucose
easurements that increased to 126 mg/dl) (27).
tatistical analyses. The primary study hypothesis was that
/S  N would be superior to N with respect to percent
hange from baseline in LDL-C after 24 weeks of treat-
ent. If the primary hypothesis was found to be significant,
hen the secondary efficacy hypotheses were tested using an
rdered testing strategy to control for multiplicity in testing
he hypothesized efficacy endpoints. Secondary end points,
ll assessed as percent change from baseline to week 24,
ere specified in the protocol and tested in the following
rder: 1) non–HDL-C (E/S  N vs. N); 2) HDL-C (E/S
N vs. E/S); 3) TG (E/S  N vs. E/S); 4) LDL-C (E/S
N vs. E/S); and 5) non–HDL-C (E/S  N vs. E/S).
ther secondary variables included percent change from
aseline to week 24 in total cholesterol (TC), apolipoprotein
Apo)B, ApoA-I, lipid/lipoprotein ratios, and high-
ensitivity C-reactive protein (hsCRP). No strategy for
ultiplicity was applied to these variables.
For the primary study hypothesis, LDL-C change, it
as expected that there would be 94% power to detect a
Figure 1 Patient Disposition
AE  adverse experience; ALT  alanine aminotransferase; AST  aspartate amin
LDL-C  low-density lipoprotein cholesterol; mITT  modified intent-to-treat populapercentage point difference between E/S  N versus N, rssuming a within-group standard deviation for an
DL-C percent change of 15% at 24 weeks. Treatment
roup differences were compared by an analysis of covari-
nce model with terms for treatment, baseline LDL-C
nd triglyceride values, and gender for all secondary
fficacy variables except triglycerides and hsCRP. For
riglycerides, percent change values were transformed to
anks based on normal scores before analysis and
etween-treatment group differences were assessed by
odges-Lehman location shift. The hsCRP was first
ransformed to the log-ratio of week 24 to baseline, and
reatment differences were assessed by the delta method.
roportions of patients experiencing AEs were compared
etween treatment groups using the Fisher exact test.
hanges from baseline in fasting glucose levels were
ompared by an analysis of covariance. All significance
ests were 2-tailed with alpha  0.050.
esults
atient demographics. A total of 2,697 patients were
creened at 106 sites in the U.S., of which 1,220 were
ferase;
SH  thyroid stimulating hormone; wk  week.otrans
tion; Tandomized to treatment with N (n  272) or with E/S
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April 22, 2008:1564–72 Ezetimibe/Simvastatin and Extended-Release Niacinn  272) or with E/S  N (n  676). The disposition of
atients is illustrated in Figure 1. The Completers popula-
ion included 770 (63%) and the mITT included 1,112
91%) of the randomized patients. Flushing was the primary
eason for study discontinuation in the N-containing groups
12.1% for N; 9.9% for E/S  N; 0.4% for E/S).
There were generally no clinically meaningful differences
n the distribution of baseline characteristics of all random-
zed patients among treatment groups (Table 1). About 28%
f the patients had CHD or CHD risk equivalent status
approximately 15% diabetes, approximately 6% non-CHD
orms of atherosclerosis), and half of the patients in each
reatment group (slightly higher for E/S) had metabolic
yndrome (3). The baseline levels of lipids and other factors
ere well balanced among treatment groups (Table 2).
ean baseline levels of LDL-C and HDL-C were 156
g/dl and 50.5 mg/dl, respectively. The median baseline
evel of triglycerides was 156 mg/dl. Baseline levels were also
imilar in the mITT population (Online Appendix A).
fficacy variables. At 24 weeks, the percent reductions
rom baseline in LDL-C, non–HDL-C, triglycerides,
poB, and in ratios (TC/HDL-C, LDL-C/HDL-C,
poB/ApoA-I, non–HDL-C/HDL-C) were significantly
reater after E/S  N treatment compared with N or E/S
aseline Characteristics of All Randomized Patients
Table 1 Baseline Characteristics of All Randomized Patients
Age, yrs, mean (SD)
Female, n (%)
Race, n (%)
Asian
Black
Hispanic
Other
White
Body mass index (kg/m2), mean (SD)
Fasting glucose (mg/dl), mean (SD)
NCEP risk category n (%)
CHD/CHD risk equivalent*
High risk with AVD
CHD
Other forms of atherosclerosis†
High risk without AVD
Diabetes
2 CHD (10 yrs 20%) risk factors
Metabolic syndrome,‡ n (%)
Waist circumference 102 cm (male) or 88 cm (female)
TG 150 mg/dl
HDL-C 40 mg/dl (male) or 50 mg/dl (female)
Blood pressure 130/85 mm Hg or on antihypertensive medication
Fasting glucose 100 mg/dl or diabetic
Patients with CHD and CHD risk equivalents may be in more than 1 category of CHD, other forms
or more occasions, or a diagnosis of diabetes, or use of antidiabetic medications). †Other forms o
isease, TIA, and stroke. ‡Defined as having 3 of the 5 following characteristics.
AVD atherosclerotic vascular disease; CHD coronary heart disease; E/S ezetimibe/simvas
DL-C  high-density lipoprotein cholesterol; N  extended-release niacin (titrated to 2 g); NCEPp  0.001) (Table 3). Increases in HDL-C with E/S  N tere significantly larger than those with E/S (p  0.001),
nd were similar to those with N. The percent change in
C was significantly greater in the E/S N group versus N
p  0.001) and was comparable to E/S. Increases in
poA-I levels were significantly larger in the E/S  N
N
(n  272)
E/S
(n  272)
E/S  N
(n  676)
56.4 (10.6) 57.5 (10.3) 56.9 (10.9)
136 (50.0) 120 (44.1) 352 (52.1)
11 (4.0) 4 (1.5) 11 (1.6)
13 (4.8) 17 (6.3) 38 (5.6)
14 (5.1) 11 (4.0) 49 (7.2)
3 (1.1) 0 (0.0) 2 (0.3)
231 (84.9) 240 (88.2) 576 (85.2)
30.1 (5.9) 30.3 (6.0) 29.8 (5.5)
101.4 (19.4) 101.6 (14.1) 101.6 (18.1)
69 (25.4) 84 (30.9) 183 (27.1)
29 (10.7) 36 (13.2) 77 (11.4)
16 (5.9) 22 (8.1) 60 (8.9)
16 (5.9) 18 (6.6) 34 (5.0)
40 (14.7) 48 (17.6) 106 (15.7)
40 (14.7) 43 (15.8) 105 (15.5)
15 (5.5) 22 (8.1) 42 (6.2)
127 (46.7) 156 (57.4) 319 (47.2)
142 (52.2) 150 (55.1) 363 (53.7)
138 (50.7) 155 (57.0) 347 (51.3)
94 (34.6) 91 (33.5) 217 (32.1)
166 (61.0) 181 (66.5) 431 (63.8)
117 (43.0) 153 (56.3) 305 (45.1)
rosclerosis, and diabetes (where diabetes is defined as baseline fasting glucose  126 mg/dl on
osclerosis are peripheral arterial disease, abdominal aortic aneurysm, symptomatic carotid artery
/20 mg; E/S N ezetimibe/simvastatin 10/20 mg niacin (extended release, titrated to 2 g);
nal Cholesterol Education Program; TG  triglycerides.
aseline Summary for Lipid/Lipoproteins and hsCRP
Table 2 Baseline Summary for Lipid/Lipoproteins and hsCRP
Baseline Measure
(mg/dl)
Baseline Mean (SD)
N
(n  166)
E/S
(n  212)
E/S  N
(n  391)
LDL-C 157.1 (21.9) 155.4 (21.7) 156.9 (23.0)
Non–HDL-C 191.0 (28.0) 190.8 (28.1) 190.9 (26.1)
HDL-C 50.5 (13.7) 49.9 (13.9) 50.5 (13.2)
TG median* 148.0 (88.4) 158.0 (100.0) 159.0 (93.0)
TC 241.5 (27.6) 240.6 (28.4) 241.4 (27.5)
TC/HDL-C 5.1 (1.2) 5.1 (1.3) 5.0 (1.2)
LDL-C/HDL-C 3.3 (0.9) 3.3 (0.9) 3.3 (0.8)
Non–HDL-C/HDL-C 4.1 (1.2) 4.1 (1.3) 4.0 (1.2)
ApoB 149.9 (20.1) 151.2 (21.8) 151.5 (21.0)
ApoA-I 163.9 (27.9) 166.1 (28.5) 165.8 (27.9)
ApoB/ApoA-I 0.9 (0.2) 0.9 (0.2) 0.9 (0.2)
hsCRP* 2.0 (3.8) 2.1 (3.5) 2.3 (3.4)
Robust standard deviation was calculated as interquartile range (IQR)/1.075, where IQR  3rd
uartile  1st quartile.of athe
f atherApo  apolipoprotein; hsCRP  high-sensitivity C-reactive protein; LDL-C  low-density lipopro-
ein cholesterol; TC  total cholesterol; other abbreviations as in Table 1.
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Ezetimibe/Simvastatin and Extended-Release Niacin April 22, 2008:1564–72roup compared with E/S (p 0.001) and were comparable
ith N. Reduction of hsCRP with E/S  N was signifi-
antly greater than with N (p  0.005).
Relatively similar results were obtained in the mITT
nalysis for all efficacy variables (Online Appendix B). In
articular, the significance of treatment group differences for
ll reported efficacy variables was the same for both popu-
ations.
ime-related and dose-related effects. Both E/S and E/S
N treatments reduced LDL-C levels from baseline by
pproximately 53% at week 4 (Fig. 2A). Throughout the
6-week titration period to the maximum N dose (2 g),
DL-C levels continued to decrease for the E/S  N
roup, and then were maintained through 24 weeks. The
DL-C levels remained constant in the E/S group from 4
o 24 weeks. For the N group, LDL-C declined gradually
rom baseline levels during 24 weeks. The percent change in
DL-C was significantly greater for E/S  N compared
ith N (p  0.001) for all time points, and compared with
he E/S group, this difference became significant at 12
eeks.
With increasing doses of N to 2 g, levels of HDL-C
ncreased substantially from baseline in the N and E/S  N
roups throughout the 16-week titration period and then
ontinued to increase (to 28% to 30%) from 16 to 24 weeks,
lthough at a lesser rate (Fig. 2B). There was a small
ncrease in HDL-C levels from baseline during 24 weeks
ith E/S treatment. The increase in HDL-C was signifi-
antly greater for E/S  N compared with E/S at all time
oints (p 0.001), and compared with N through 12 weeks
p  0.001), after which these differences became nonsig-
ificant.
Levels of triglycerides declined at 4 weeks by approxi-
ercent Change From Baseline in Efficacy Parameters
Table 3 Percent Change From Baseline in Efficacy Parameters
Parameter
Percent Change From Baseline*
N
(n  166)
E/S
(n  212)
E/S 
(n  3
LDL-C 20.1 53.5 58
Non–HDL-C 22.0 47.9 55
HDL-C 28.1 8.1 30
TG (median) 30.1 23.7 42
TC 11.6 36.4 37
TC/HDL-C 29.3 40.3 50
LDL-C/HDL-C 35.8 56.2 66
Non–HDL-C/HDL-C 37.0 50.8 63
(n  163) (n  205) (n  3
ApoB 19.5 40.1 48
ApoA-I 10.7 3.6 11
ApoB/ApoA-I 26.3 41.7 52
(n  162) (n  207) (n  3
hsCRP‡§ 6.7 30.0 28
reatment difference E/SNminus N and E/SNminus E/S. *Least-squaresmeans. †These p
nd were all considered statistically significant according to the pre-specified closed testing procedu
f log transformation. §Treatment differences are differences in geometric mean percent change
Abbreviations as in Tables 1 and 2.ately 28% for E/S and E/S  N (Fig. 2C). The levels of iriglycerides were maintained for the E/S group. For the N
nd E/S  N groups, triglyceride levels decreased contin-
ously during the 16-week titration period with increasing
oses of niacin, and then were maintained throughout 24
eeks. The reduction in triglyceride levels was significantly
reater for E/S  N compared with N over 24 weeks
p  0.001) and was also significantly greater compared
ith E/S from weeks 8 to 24 (p  0.001).
The profiles of percent change over time for these variables
n the mITT population (Online Appendix C) were generally
imilar to those of the Completers population.
afety. Of the 1,220 randomized patients, 1,214 received
t least 1 dose of study treatment and were included in the
afety analysis. The incidence of clinical AEs was higher in
he N and E/S  N treatment groups than the E/S group
Table 4), mostly attributed to a greater occurrence of
ushing-related AEs in the N-containing groups (Table 5).
he number of patients who experienced clinical and
rug-related AEs leading to study drug discontinuations
as similar in the N (25.0%) and E/S  N (23.3%) groups
nd lower in the E/S (9.6%) group. One death due to
troke, considered by the investigator not to be study
rug–related, occurred in the N group. Gallbladder-related
Es developed in 2 subjects, 1 of whom (E/S group) had a
holecystectomy.
Incidences of laboratory AEs were comparable for the N
7.0%), E/S (7.4%), and E/S  N (5.1%) groups. Similar
umbers of laboratory AEs resulted in study discontinuation
n the N and E/S  N groups, with no occurrences in the
/S group. No serious laboratory AEs occurred during the
tudy. The percentages of patients with consecutive 3 
LN elevations in alanine aminotransferase/aspartate ami-
otransferase and CK levels 10  ULN were not signif-
Treatment Difference
E/S  N
vs. N p Value
E/S  N
vs. E/S p Value
38.4 0.001† 4.9 0.001†
33.5 0.001† 7.7 0.001†
2.1 0.05 22.1 0.001†
11.7 0.001† 18.7 0.001†
26.3 0.001 1.6 0.05
21.1 0.001 10.1 0.001
30.3 0.001 9.9 0.001
26.6 0.001 12.9 0.001
28.6 0.001 8.1 0.001
0.3 0.05 7.4 0.001
26.0 0.001 10.6 0.001
21.7 0.005 1.6 0.05
re unadjusted, represent the significance level of the primary hypothesis or secondary hypotheses,
ther p values are unadjusted. ‡Geometric mean based on back-transformation via exponentiation
baseline calculated using the delta method.N
91)
.5
.6
.2
.5
.9
.4
.1
.6
83)
.1
.0
.3
81)
.4
values a
re. All ocantly different among the treatment groups (Table 5). One
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April 22, 2008:1564–72 Ezetimibe/Simvastatin and Extended-Release Niacinatient (E/SN group) had CK10 ULN and myalgia
hat were considered by the investigator to be related to
trenuous exercise and not to study drug.
A total of 22 patients had AEs of increased fasting
lucose, with the highest incidence occurring in the N
2.9%) versus E/S (1.8%) and E/S  N (1.3%) groups. The
ean changes from baseline to week 24 in fasting glucose
ere 3.6 and 2.6 mg/dl, respectively, for the N and E/S 
groups, compared with 0.1 mg/dl for the E/S group
p  0.022, E/S  N vs. E/S). Fasting glucose levels
ncreased to a maximum of approximately 7.5% above
aseline levels during the first 12 weeks in both groups
eceiving N, and then decreased to levels of approximately
.0% above baseline at 24 weeks (Fig. 3).
A total of 32 patients met the criteria for new onset of
iabetes in the N (2.2%), E/S (0.9%), and E/S  N (4.4%)
roups (Table 5). The proportion of patients in the E/S 
versus N groups with new onset of diabetes was compa-
able and the difference between the E/S  N versus E/S
roups was significant (p  0.009).
iscussion
his study shows that once-daily coadministration of E/S at
0/20 mg/day with N at 2 g/day provides substantial
mprovements in LDL-C lowering, HDL-C raising, and
ther aspects of the lipoprotein profile in patients with type
Ia and IIb hyperlipidemia. The combination (E/S  N)
ignificantly reduced levels of LDL-C and other lipids in
omparison to either agent alone and elicited increases in
DL-C, which were significantly higher than those gen-
rated by E/S and similar to those induced by N alone. This
-drug combination was generally well tolerated, aside from
nticipated niacin-associated flushing.
In this study, this combination of E/S  N resulted in a
8.5% reduction of LDL-C levels from baseline, which was
ignificantly greater than that of the usual recommended
tarting dose (10/20 mg/day) of E/S (53.5%), and compa-
able to that observed previously in other studies for the
aximum prescribed dose of E/S (approximately 60% at
0/80 mg) (22–25). The reduction of LDL-C levels by the
riple combination was also significantly greater than N
lone and was more effective than, or at least comparable to,
reviously studied combinations of niacin and statins or bile
cid sequestrants, which reduced LDL-C by 31% to 49%
rom baseline (4,5,10–13,15). E/SN was also much more
ffective in LDL-C lowering than the triple combination of
iacin, gemfibrozil, and cholestyramine, which lowered
DL-C from baseline by 22% (20).
The combination E/S has been shown to slightly increase
DL-C levels from baseline by 6% to 10% (22–25). When
ombined with N in this study, HDL-C levels were
ncreased significantly more from baseline (30.2%) com-
ared with E/S alone (8.1%) but not compared with N
onotherapy (28.1%). The increase in HDL-C levels was-70
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o 43% from baseline (4,5,8–17).
The improvements in LDL-C and triglycerides after E/S
N therapy were related to the sustained effect of E/S and
o increasing doses of N. These effects persisted throughout
ummary of Clinical Adverse Experiences
Table 4 Summary of Clinical Adverse Experiences
Clinical Adverse
Experience
N
(n  272)
E/S
(n  272)
n % n %
1 event 224 82.4 171 62.9
Drug-related* 163 59.9 50 18.4
Serious† 7 2.6 7 2.6
Serious drug-related* 0 0.0 1 0.4
Deaths 1‡ 0.4 0 0.0
Discontinuations§ 68 25.0 26 9.6
Drug-related* 60 22.1 17 6.3
Serious 2 0.7 2 0.7
Serious drug-related* 0 0.0 0 0.0
Determined by the investigator to be possibly, probably, or definitely drug-related. †Serious ad
astrointestinal hemorrhage, 1 cardiac chest pain, 1 noncardiac chest pain, 1 perirectal abscess, 1
syncope, 1 thrombosis. For E/S: 1 acute coronary syndrome, 1 spondylolisthesis, 1 pancreatitis, 1
ailure, 1 asthma, 1 pulmonary embolism, 1 pulmonary edema. For N: 1 chest pain, 1 noncardiac c
Attributed to a cerebrovascular accident, not drug-related. §The number of patients who disconti
atients had an adverse event before randomization that lead to discontinuation during active tre
re counted as discontinuing in Figure 1. Six other patients had an adverse event that began on tre
vent that began while on treatment but did not lead to discontinuation until Part 2 of this study.
ut are counted as having completed the study in Figure 1. Most common reasons for drug-relate
5 pruritus/generalized pruritus, 70 flushing, 4 rash/rash pruritic/rash papular, 4 urticaria, 4 mya
—  not estimable; CI  confidence interval; other abbreviations as in Table 1.
re-Specified Laboratory and Clinical Adverse Events
Table 5 Pre-Specified Laboratory and Clinical Adverse Events
Pre-Specified Laboratory
Adverse Experiences
N
(n  272)
E/S
(n  272) (
m/n % m/n % m
ALT 3  ULN, consecutive† 1/252 0.4 1/260 0.4 3/
AST 3  ULN, consecutive† 1/252 0.4 1/260 0.4 2/
ALT and/or AST 3  ULN,
consecutive†
1/252 0.4 1/260 0.4 4/
CK
10  ULN‡ 0/252 0.0 1/260 0.4 4/
10  ULN with muscle
symptoms
0/252 0.0 0/260 0.0 1§/
10  ULN with muscle
symptoms considered to
be drug-related
0/252 0.0 0/260 0.0 0/
Discontinuation due to flushing 33/272 12.1 1/272 0.4 66/
Gallbladder-related adverse
events
0/272 0.0 1/272 0.4 1/
Cholecystectomy 0/272 0.0 1/272 0.4 0/
New onset of diabetes 5/232 2.2 2/229 0.9 25/
p values from Fisher exact test. †This category includes those patients with: 1) 2 consecutive meas
y a measurement 3  ULN that was taken more than 2 days after the last dose of study medi
1 considered drug-related) and did not result in discontinuation. Consecutive ALT/AST3 ULN a
atients discontinued. ‡One patient in the E/S group had consecutive CK 10  ULN without mu
atients in the E/S  N group had CK 10  ULN without muscle symptoms that resolved (3 con
clinical adverse event of myalgia that was not considered by the investigator to be drug-related; t
g/dl and 125 mg/dl at randomization (impaired fasting glucose [27]) and all but 1 (E/S  N) m
iabetes and placed on metformin, 2 patients in E/S  N group were diagnosed with diabetes, 1
—  not estimable; ALT  alanine aminotransferase; AST  aspartate aminotransferase; CK 
atients with one or more laboratory tests post-baseline), and for new onset of diabetes, n  number of p
able 1.he 24 weeks of the study. In addition, HDL-C levels
ncreased substantially during the N dose escalation period
nd continued to increase through 24 weeks. These results
re consistent with those observed for the combination of
xtended-release niacin and lovastatin (Advicor, Kos Phar-
E/S  N
(n  670) E/S  N vs. N E/S  N vs. E/S
n %
Difference
(95% CI)
Difference
(95% CI)
504 75.2 7.1 (12.4 to1.3) 12.4 (5.9 to 19.0)
363 54.2 5.7 (12.5 to 1.3) 35.8 (29.5 to 41.4)
14 2.1 0.5 (3.3 to 1.4) 0.5 (3.3 to 1.4)
0 0.0 — —
0 0.0 — —
156 23.3 1.7 (8.0 to 4.1) 13.7 (8.6 to 18.2)
129 19.3 2.8 (8.8 to 2.7) 13.0 (8.5 to 16.9)
5 0.7 — —
0 0.0 — —
vents. For E/S  N: 1 anemia, 1 acute coronary syndrome, 1 coronary artery disease, 1 lower
onia, 1 staphylococcus infection, 1 muscle strain, 2 osteoarthritis, 2 breast cancer, 1 paresthesia,
pain, 1 cholecystitis, 1 fibula fracture, 1 tibia fracture, 1 dehydration, 1 cerebral infarction, 1 renal
in, 1 pneumonia, 1 osteoarthritis, 1 basal cell carcinoma, 2 cerebrovascular accident, 1 dizziness.
ecause of a clinical adverse event in this table differs from Figure 1 by 15 patients. Four of these
and are not counted as having discontinued because of a clinical adverse event in this table, but
but did not lead to discontinuation until the last visit of Part 1 of this study, and 5 had an adverse
1 patients were counted as having a clinical adverse event causing discontinuation in this table,
ntinuations. For N: 7 pruritus/rash pruritic, 33 flushing. For E/S: 4 myalgia, 4 rash. For E/S  N:
N
70) E/S  N vs. N E/S  N vs. E/S
%
Difference
(95% CI) p Value*
Difference
(95% CI) p Value*
0.5 0.1 (1.7 to 1.1) 0.99 0.1 (1.7 to 1.1) 0.99
0.3 0.1 (1.9 to 0.9) 0.99 0.1 (1.8 to 0.9) 0.99
0.7 0.3 (1.6 to 1.3) 0.99 0.3 (1.5 to 1.4) 0.99
0.7 0.7 (0.9 to 1.7) 0.33 0.3 (1.5 to 1.4) 0.99
0.2 0.2 (1.3 to 0.9) 0.99 0.2 (1.3 to 0.9) 0.99
0.0 — — — —
9.9 2.3 (7.1 to 1.9) 0.294 9.5 (6.8 to 12.0) 0.001
0.1 0.1 (1.2 to 0.8) 0.99 0.2 (1.9 to 0.5) 0.49
0.0 — — 0.4 (2.1 to 0.3) 0.29
4.4 2.2 (0.9 to 4.6) 0.153 3.5 (0.9 to 5.6) 0.009
nts3 ULN, 2) a single, last measurement3 ULN, or 3) a measurement3 ULN followed
Two patients in the N and E/S groups experienced consecutive ALT/AST 3  ULN that resolved
events in all 4 patients in the E/S N group also resolved (3 considered drug-related), 2 of these
mptoms that resolved (considered drug-related) and did not result in study discontinuation. Four
drug-related), 3 discontinued. §The CK elevation in this patient (E/S  N) was accompanied by
nt recovered from the event. All patients in this category had fasting glucose levels between 100
riteria of 2 consecutive fasting glucose 126 mg/dl; 1 patient in E/S group was diagnosed with
m was placed on metformin.
e kinase; m/n  (number of patients within the adverse experience category/number of treatedverse e
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nd triglyceride levels achieved during a similar niacin
itration schedule were maintained for 1 year, and HDL-C
evels continued to increase throughout the year (12,14).
esults relating to the longer-term effects of the E/S  N
ombination will be further elucidated by Part 2 of the
verall study.
Consistent with the broad lipid-altering effects of niacin
emonstrated in other studies, E/S  N also reduced levels
f several other lipid parameters, including non–HDL-C,
C, ApoB, and TC/HDL-C, LDL-C/HDL-C, ApoB/
poA-I, non–HDL-C/HDL-C significantly more than
/S or N alone (10–12,14,16,20). These effects, in addition
o the improvements in LDL-C and triglyceride lowering,
long with the HDL-C raising effect, suggest that E/S N
ay have considerable value as a treatment option for
igh-risk patients with combined dyslipidemia.
The primary efficacy results of this trial for E/S  N,
ssessed in the Completers population comprised of those
ndividuals who completed the study at the 2 g maximum
ose, were well supported by those of the mITT analysis. At
4 weeks, reductions in levels of LDL-C (58.5% and
56.8%) and triglycerides (42.5% and 39.9%), and
ncreases in HDL-C (30.2% and 25.1%) in the Completers
nd mITT populations, respectively, were relatively compa-
able. Time-related and dose-related effects and changes in
ther efficacy variables were also comparable; moreover, the
ignificance of treatment group differences for all efficacy
ariables was the same for both populations (Online Ap-
endixes B and C). Changes in some parameters were
umerically higher in the N-containing groups of the
ompleters population, reflecting the efficacy assessment at
g N in this population versus a range of doses (0.5 to 2 g)
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Figure 3 Time and Dose Effect on Fasting Glucose
Percent change from baseline in fasting glucose during 24 weeks.
Abbreviations as in Figure 2.n the mITT population. aCombined E/S  N treatment was generally well toler-
ted in this study and showed a safety profile consistent with
rior experience using these agents alone or in combination
ndicating that E/S  N may be an option for use in
atients at high risk for CHD including those with diabetes,
etabolic syndrome, and obesity, in whom polypharmacy
ay be a concern (4–7,22–26). The rates of serious AEs
ere comparable for all treatment arms, and there were no
tatistically significant differences in muscle, liver, and
astrointestinal AEs. Study discontinuations were higher in
he groups receiving N, as expected for the 2-g maximum
ose, because of N-associated flushing (7,26). Clinical toler-
nce of niacin can be improved through patient counseling/
ducation, bedtime dosing with a low-fat snack, prior admin-
stration of aspirin or nonsteroidal anti-inflammatory agent,
nd slow dose titration, all of which were recommended in this
tudy. Even with these measures, this side effect can limit
ompliance with niacin therapy; however, new strategies are in
evelopment that may enable more patients to use niacin at
igher doses (28,29). Although the maximum 2-g dose was
ssessed as a primary end point in this study, it should be noted
hat the average Niaspan dose used by patients in the U.S. is
pproximately 1 g (30). As reported in previous studies and in
he extended-release niacin product circular, niacin therapy can
e associated with elevations in fasting glucose levels
10,20,26,31,32). This effect was also seen in our study,
lthough the increase in fasting glucose lessened over time, as
as been the case in other studies (4,31).
Epidemiological analyses and a meta-analysis of clinical
ipid trials have suggested that a 40% reduction in LDL-C
nd a 30% increase in HDL-C together may reduce
oronary artery disease risk by approximately 70% (5).
imited placebo-controlled trials suggest that niacin as
onotherapy and in combination with LDL-lowering
gents improves various cardiovascular end points by 26% to
9% (15,16,19–21). Ongoing studies will provide an assess-
ent of the effect of niacin/statin combination therapy on
ipid-depletion in atherosclerotic plaques and clinical out-
omes in CHD patients (33–35). Other studies are also
ngoing to specifically define the effects of E/S therapy on
linical outcomes (36–38).
The significant improvements in the overall lipid and
ipoprotein profile attained after 24 weeks of therapy with
he triple combination E/S  N in this study are consistent
ith the known, complementary lipid-altering effects of the
omponent drugs at these doses. Similarly, the observed
ushing side effects, discontinuation rates of the drug
roups, and the low and infrequent rates of clinical and
aboratory AEs did not seem to exceed the known frequen-
ies for the individual components of this combination.
his study also documented the time-related and dose-
elated effects of niacin on HDL-C and glucose raising, but
uggest the glucose effect is somewhat attenuated over time.
he continuation of this study for an additional 40 weeks
ill provide a longer-term evaluation of its safety, lipid-ltering efficacy, and time-related effects, and will be re-
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mpact of this triple combination therapy awaits further
tudy in large, randomized trials with adjudicated clinical
fficacy and safety outcomes.
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APPENDIX
or additional tables and an additional figure, please see the online version
f this article.
